Novel Pyrroloquinazolines as Anti-cancer Agents

Case ID:
Web Published:

Novel and Effective Compounds for Triple Negative Breast Cancer

Researchers at Oregon Health & Science University have discovered a novel lead compound that is active against triple negative breast cancer through what is believed to be a novel (unknown at this point-target identification underway) mechanism of action. The lead compound is not cytotoxic and represents a tremendous opportunity to develop the first selective drug for treatment of triple negative breast cancer. This intellectual property provides a platform for a drug development program focused on lead optimization of novel compounds acting under a novel mechanism of action. 

United States Non-Provisional patent and PCT patent applications filed.

Investigator: Xiangshu Xiao, PhD

OHSU Technology 1851 is available for exclusive and non-exclusive licensing and/or collaborative co-development.

If interested in learning more, please contact Travis Cook, Senior Technology Development Manager at or (503) 494-5861 and reference Tech Id No. 1851.  

Patent Information:
For Information, Contact:
Travis Cook
Senior Technology Development Manager
Oregon Health & Science University
Xiangshu Xiao
Jingjin Chen
Bingbing Li
Therapeutics - Cancer
© 2019. All Rights Reserved. Powered by Inteum